Cargando…

Extent of liver inflammation in predicting response to interferon α & Ribavirin in chronic hepatitis C patients: a cohort study

BACKGROUND: Liver inflammation due to HCV infection leads to fibrosis, which is an independent predictor of treatment response to interferon therapy in Chronic Hepatitis C (CHC) patients. This relationship has not been studied for liver inflammation on pretreatment liver biopsy and End of Treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mirza, Shirin, Siddiqui, Amna Rehana, Hamid, Saeed, Umar, Muhammad, Bashir, Shaheena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502580/ https://www.ncbi.nlm.nih.gov/pubmed/22697612 http://dx.doi.org/10.1186/1471-230X-12-71

Ejemplares similares

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
por: Akram, Madiha, et al.
Publicado: (2011)

Serous Retinal Detachments Complicating Interferon-α and Ribavirin Treatment in Patients with Hepatitis C
por: Modorati, Giulio, et al.
Publicado: (2011)

Autoimmune Hepatitis Triggered by Treatment With Pegylated Interferon α-2a and Ribavirin for Chronic Hepatitis C
por: Rathi, Chetan, et al.
Publicado: (2015)

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
por: Gonçales, Fernando L, et al.
Publicado: (2010)

Incidence of retinopathy in chronic hepatitis C patients treated with pegylated interferon alpha 2a and ribavirin combination therapy
por: Kashif, Muhammad, et al.
Publicado: (2015)

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy
por: Chopra, Amit, et al.
Publicado: (2015)

Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection
por: Kagawa, Tatehiro, et al.
Publicado: (2010)

Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea
por: Cho, Hyun Chin, et al.
Publicado: (2013)

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
por: Carvalho-Filho, Roberto J, et al.
Publicado: (2010)

Interferon-Alpha Induced and Ribavirin Induced Thyroid Dysfunction in Patients with Chronic Hepatitis C
por: Nadeem, Amina, et al.
Publicado: (2010)

Treatment of chronic hepatitis C patients not responding to combination therapy with ribavirin and interferon α — hype or hope?
por: Vogel, Wolfgang
Publicado: (2004)

354 Autoimmune Hepatitis Misdiagnosed as Hepatitis C Responding to Interferon/Ribavirine Therapy
por: Pijak, Michal R., et al.
Publicado: (2012)

Concurrent Autoimmune Hepatitis and Grave's Disease in Hepatitis C during Pegylated Interferon α-2a and Ribavirin Therapy
por: Trikudanathan, Guru V., et al.
Publicado: (2011)

Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C
por: Aizawa, Nobuhiro, et al.
Publicado: (2013)

The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with combination Interferon-α2β and Ribavirin
por: Tran, Huy A, et al.
Publicado: (2005)

Adverse Skin Reactions due to Ribavirin in Hepatitis C Combination Therapy with Pegylated Interferon-α(2a)
por: Shindo, Masahisa, et al.
Publicado: (2013)

Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance
por: Pennisi, Manuela, et al.
Publicado: (2017)

Cutaneous side effects of combination therapy of pegylated interferon 2α and ribavirin
por: Raducan, Anca, et al.
Publicado: (2014)

Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with α-interferon and ribavirin: Rosuvastatin reduces NAFLD in HCV patients
por: Malaguarnera, Michele, et al.
Publicado: (2011)

Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens
por: Younossi, Zobair M., et al.
Publicado: (2016)

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy
por: Pradat, Pierre, et al.
Publicado: (2015)

Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin
por: Danilovic, Debora Lucia Seguro, et al.
Publicado: (2011)

Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype
por: Guo, Xiaoyan, et al.
Publicado: (2012)

Treatment of acute hepatitis C virus infection with interferon-α 2b and ribavirin: Case report and review of the literature
por: Leblebicioglu, Hakan, et al.
Publicado: (2002)

Supervised conventional interferon α2a in combination with ribavirin therapy is the preferred alternative for treatment of chronic hepatitis C
por: Rehan, Harmeet Singh, et al.
Publicado: (2014)

Prediction of sustained virologic responses to combination therapy of pegylated interferon-α and ribavirin in patients with chronic hepatitis C infection
por: Ismail, Mona H.
Publicado: (2013)

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
por: Karino, Y, et al.
Publicado: (2014)

Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study
por: Hsieh, Ming-Han, et al.
Publicado: (2022)

Efficacy of Interferon α-2b and Ribavirin against West Nile Virus In Vitro
por: Anderson, John F., et al.
Publicado: (2002)

Role of MicroRNA Modulation in the Interferon-α/Ribavirin Suppression of HIV-1 In Vivo
por: Abdel-Mohsen, Mohamed, et al.
Publicado: (2014)

Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4
por: Kozielewicz, Dorota, et al.
Publicado: (2018)

Relapse of Vogt-Koyanagi-Harada Disease during Interferon-α and Ribavirin Therapy in a Case of Chronic Viral Hepatitis C
por: Soma, Miho, et al.
Publicado: (2011)

Case Report: Severe Interstitial Pneumonitis Secondary to Pegylated Interferon α-2b and Ribavirin Treatment of Hepatitis C Infection
por: Fuhrmann, Valentin, et al.
Publicado: (2004)

Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
por: Rodríguez-Lojo, R., et al.
Publicado: (2010)

Hepatitis C virus quasispecies in chronically infected children subjected to interferon–ribavirin therapy
por: Figlerowicz, Magdalena, et al.
Publicado: (2010)

Cryptococcal meningitis in a patient with chronic hepatitis C treated with pegylated-interferon and ribavirin
por: Lee, Tae-Hee, et al.
Publicado: (2014)

Retreatment of hepatitis C non-responsive to Interferon. A placebo controlled randomized trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]
por: Veldt, Bart J, et al.
Publicado: (2003)

Regression of esophageal varices and splenomegaly in two patients with hepatitis-C-related liver cirrhosis after interferon and ribavirin combination therapy
por: Lee, Soon Jae, et al.
Publicado: (2016)

Successful natural interferon-β plus ribavirin therapy in a chronic hepatitis C patient after discontinuation of interferon-α treatment due to arrhythmia and interstitial pneumonia
por: Sato, Akira, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_s3f3lotui4du007k85n170m3je